Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: A multicenter retrospective observational study

Lopalco, Giuseppe; Emmi, Giacomo; Gentileschi, Stefano; Guerriero, Silvana; Vitale, A.; Silvestri, Elena; Becatti, Matteo; Cavallo, Iacopo; Fabiani, Claudia; Frediani, Bruno; Iannone, Florenzo; Cantarini, Luca

doi:10.1080/14397595.2017.1285857

Cited by 44 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…suggesting that the role of certozilumab might be limited in VBD. 19 In the present study, the methylprednisolone dosage significantly decreased at the third month of TNFα initiation similar to previous reports. 7,14 This is especially important in patients with BD refractory to conventional ISs as these patients usually receive a high cumulative dose of CSs.…”

Section: Literature Reviewsupporting

confidence: 92%

“…For refractory or intolerant cases to IFX or ADA, Lapalco et al presented 13 BD patients treated with certozilumab with three patients having vascular involvement. Although the vascular outcome is not clear in these three patients, 2 out of 3 seem to have changed their treatment to IFX or golimumab, suggesting that the role of certozilumab might be limited in VBD …”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature

et al. 2020

View full text Add to dashboard Cite

Objectives Vascular involvement is one of the major causes of morbidity and mortality in Behçet's disease (BD) patients. Immunosuppressive (IS) agents are the mainstay of vascular BD (VBD) treatment; however, up to one‐third of patients relapse under conventional ISs. In this case series, we present the results of tumor necrosis factor‐alpha (TNFα) inhibitor use for the treatment of VBD patients who were refractory to conventional ISs and corticosteroids. Methods This retrospective multicenter study included 27 refractory VBD patients treated with TNFα inhibitor agents. All data were acquired from patient charts. Results Complete clinical remission was achieved in 22 (80%) patients within 3 months of the initiation of TNFα inhibitors. Infliximab was the first choice of TNFα inhibitor in 24 and adalimumab in three patients. The median daily dose of corticosteroids significantly decreased at 3 months. A trend toward a higher rate of complete remission was observed with concomitant IS use compared to monotherapy of TNFα inhibitors (93% vs 67%, P = .09). Serious side effects were observed in two patients (one pneumonia and one tuberculosis). Conclusion Tumor necrosis factor‐alpha inhibitors seem a highly effective option for remission‐induction of refractory VBD with an acceptable safety data. Concomitant IS use may achieve higher complete remission rates as compared to TNFα inhibitor monotherapy. Comparative efficacy and safety of biological agents for VBD require further prospective, randomized controlled studies with a longer duration of follow‐up.

show abstract

Section: Literature Reviewsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 96%

Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Vascular involvement in BS represents a clinical issue in terms of morbidity and mortality , and optimal clinical management still remains a matter of debate . Anti‐TNF agents are increasingly reported as the treatment of choice for involvement of different organs in BS ; nevertheless, only few data are available on the role of TNF inhibition in BS patients with vascular involvement .…”

Section: Discussionmentioning

confidence: 99%

Adalimumab‐Based Treatment Versus Disease‐Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome

Emmi

Vitale

Silvestri

et al. 2018

Arthritis & Rheumatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is currently US FDA‐approved for the treatment of Crohn disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It has also been studied in the management of Behçet disease with favourable, but inconclusive results …”

Section: Current Therapiesmentioning

confidence: 99%

“…It has also been studied in the management of Behçet disease with favourable, but inconclusive results. 105 Llorenc et al were the first to publish the use of certolizumab in the treatment of seven cases of chronic relapsing NIU. It was found to effectively settle active inflammation in five out of seven patients with no adverse effects encountered, leading to the suggestion that certolizumab may be of use in the management of NIU.…”

Section: Certolizumabmentioning

confidence: 99%

New therapies in development for the management of non‐infectious uveitis: A review

Hassan

Karkhur

Bae

et al. 2019

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Uveitis is a spectrum of inflammatory disorders characterized by ocular inflammation and is one of the leading causes of preventable visual loss. The main aim of the treatment of uveitis is to control the inflammation, prevent recurrences of the disease and preserve vision while minimizing the adverse effects associated with the therapeutic agents. Initial management of uveitis relies heavily on the use of corticosteroids. However, monotherapy with high‐dose corticosteroids is associated with side effects and cannot be maintained long term. Therefore, steroid‐sparing agents are needed to decrease the burden of steroid therapy. Currently, the therapeutic approach for non‐infectious uveitis (NIU) consists of a step‐ladder strategy with the first‐line option being corticosteroids in various formulations followed by the use of first‐, second‐ and third‐line agents in cases with suboptimal steroid response. Unfortunately, the agents currently at our disposal have limitations such as having a narrow therapeutic window along with their own individual potential side‐effect profiles. Therefore, research has been targeted to identify newer drugs as well as new uses for older drugs that target specific pathways in the inflammatory response. Such efforts are made in order to provide targeted and safer therapy with reduced side effects and greater efficacy. Several specially designed molecular antibodies are currently in various phases of investigations that can potentially halt the inflammation in patients with NIU. In the review, we have provided a comprehensive overview of the current and upcoming therapeutic options for patients with NIU.

show abstract

Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: A multicenter retrospective observational study

Cited by 44 publications

References 21 publications

Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature

Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature

Adalimumab‐Based Treatment Versus Disease‐Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome

New therapies in development for the management of non‐infectious uveitis: A review

Contact Info

Product

Resources

About